|
Age, y (mean; SD)
|
54.1 (12.7)
|
63.2 (12.7)
|
58.7 (13.4)
|
0.014
|
0
|
|
Gender, male (n; %)
|
15 (60)
|
21 (80)
|
36 (70.6)
|
0.104
|
0
|
|
Duration of HD, d (mean; SD)
|
144.6 (67.8)
|
145.8 (55.7)
|
145.2 (61.3)
|
0.065
|
0
|
|
Coronary calcification score (mean; SD)
|
102 (164.8)
|
2520.9 (1563.8)
|
1335 (1651)
|
<0.001
|
0
|
|
Calcium, mmol/L (mean; SD)
|
2.3 (0.2)
|
2.3 (0.3)
|
2.3 (0.2)
|
0.800
|
1
|
|
Phosphorus, mmol/L (mean; SD)
|
1.8 (0.4)
|
1.8 (0.6)
|
1.8 (0.5)
|
0.857
|
1
|
|
Albumin, g/L (mean; SD)
|
39.4 (2.9)
|
36.2 (5.2)
|
37.8 (4.5)
|
0.011
|
1
|
|
Alkaline phosphatase, U/L (mean; SD)
|
99.0 (51.9)
|
110.0 (44.5)
|
104.2 (48.2)
|
0.490
|
13
|
|
Glucose, mmol/L (mean; SD)
|
8.8 (7.2)
|
9.3 (6.9)
|
9.0 (7.0)
|
0.790
|
1
|
|
HbA1C (mean; SD)
|
0.07 (0.02)
|
0.07 (0.02)
|
0.07 (0.02)
|
0.716
|
28
|
|
C reactive protein, mg/L (mean; SD)
|
5.5 (8.2)
|
31.8 (46.1)
|
19.3 (35.7)
|
0.091
|
30
|
|
Intact PTH, pmol/L (mean; SD)
|
104.5 (129.0)
|
104.3 (83.0)
|
104.4 (108.8)
|
0.994
|
10
|
|
Uric acid, μmol/L (mean; SD)
|
380.4 (75.5)
|
372.8 (78.5)
|
376.6 (76.1)
|
0.750
|
9
|
|
URR (mean; SD)
|
65.4 (16.1)
|
66.2 (7.3)
|
65.8 (12.3)
|
0.834
|
2
|
|
Hemoglobin, g/L
|
112.76 (12.30)
|
119.69 (11.31)
|
116.29 (12.20)
|
0.041
|
0
|
|
Comorbidities
|
|
COPD (n; %)
|
9 (36 %)
|
6 (23 %)
|
15 (29.4)
|
0.311
|
0
|
|
Liver disease (n; %)
|
2 (8 %)
|
0 (0 %)
|
2 (3.9)
|
0.141
|
0
|
|
Diabetes (n; %)
|
13 (52 %)
|
18 (69 %)
|
31 (60.8)
|
0.208
|
0
|
|
Hypertension (n; %)
|
23 (92 %)
|
24 (92 %)
|
47 (92.2)
|
0.967
|
0
|
|
Systolic blood pressure, mmHg (mean; SD)
|
147.6 (23.2)
|
145.4 (22.7)
|
146.5 (22.8)
|
0.737
|
0
|
|
Diastolic blood pressure, mmHg (mean; SD)
|
78.8 (15.9)
|
80.2 (14.2)
|
79.5 (14.9)
|
0.742
|
0
|
|
Baseline Cardiovascular Disease
|
|
Myocardial infarction (n; %)
|
4 (16 %)
|
7 (27 %)
|
11 (21.6)
|
0.343
|
0
|
|
CABG (n; %)
|
2 (8 %)
|
3 (11 %)
|
5 (9.8)
|
0.671
|
0
|
|
Percutaneous coronary intervention (n; %)
|
1 (4 %)
|
5 (19 %)
|
6 (11.8)
|
0.091
|
0
|
|
Atrial fibrillation (n; %)
|
2 (8 %)
|
5 (19 %)
|
7 (13.7)
|
0.244
|
0
|
|
DVT (n; %)
|
5 (20 %)
|
0 (0 %)
|
5 (9.8)
|
0.016
|
0
|
|
Pulmonary embolism (n; %)
|
4 (16 %)
|
0 (0 %)
|
4 (7.8)
|
0.034
|
0
|
|
Cause of ESRD
|
|
Glomerulonephritis (n; %)
|
11 (44 %)
|
2 (8 %)
|
13 (25.5)
|
0.003
|
0
|
|
Polycystic kidney disease (n; %)
|
2 (8 %)
|
1 (4 %)
|
3 (5.9)
|
0.529
|
0
|
|
Diabetes mellitus (n; %)
|
6 (24 %)
|
12 (46 %)
|
18 (35.3)
|
0.098
|
0
|
|
Hypertension (n; %)
|
5 (20 %)
|
10 (38 %)
|
15 (29.4)
|
0.148
|
0
|
|
Other (n; %)
|
1 (4 %)
|
1 (4 %)
|
2 (3.9)
|
0.977
|
0
|
|
Medications
|
|
Calcium carbonate (n; %)
|
17 (68 %)
|
18 69 %
|
35 (68.6)
|
0.925
|
0
|
|
Sevelamer (n; %)
|
1 (4 %)
|
0 (0 %)
|
1 (2.0)
|
0.303
|
0
|
|
Bisphosphonates (n; %)
|
1 (4 %)
|
0 (0 %)
|
1 (2.0)
|
0.303
|
0
|
|
Warfarin (n; %)
|
4 (16 %)
|
5 (19 %)
|
9 (17.6)
|
0.762
|
0
|
|
Alfacalcidol (n; %)
|
14 (56 %)
|
9 (35 %)
|
23 (45.1)
|
0.125
|
0
|
